KCI V.A.C.Ulta Manual Del Usuario página 11

Continuous versus dPC (dynamic Pressure Control) V.A.C.
Therapy is recommended over unstable structures, such as an unstable chest wall or non-intact
fascia, in order to help minimize movement and stabilize the wound bed� Continuous therapy is
also generally recommended for patients at increased risk of bleeding, highly exudating wounds,
fresh flaps and grafts, and wounds with acute enteric fistulae.
Note: V.A.C. VeraFlo™ Therapy, due to the controlled delivery of wound
irrigation and treatment solutions, provides intermittent V.A.C.
is not recommended in the above wound types or conditions.
Patient size and Weight: The size and weight of the patient should be considered when
prescribing V�A�C� Therapy or V�A�C� VeraFlo™ Therapy� Infants, children, certain small adults and
®
elderly patients should be closely monitored for fluid loss and dehydration� Also, patients with
highly exudating wounds or large wounds in relation to the patient size and weight should be
closely monitored, as they have a risk of excessive fluid loss and dehydration� When monitoring
fluid output, consider the volume of fluid in both the tubing and canister�
spinal Cord injury (sCi): In the event an SCI patient experiences autonomic dysreflexia (sudden
changes in blood pressure or heart rate in response to stimulation of the sympathetic nervous
system), discontinue V�A�C�
stimulation and seek immediate medical assistance�
bradycardia: To minimize the risk of bradycardia, V�A�C�
must not be placed in proximity to the vagus nerve�
enteric fistulas: Wounds with enteric fistulas require special precautions to optimize V�A�C�
Therapy� Refer to V�A�C�
recommended if enteric fistula effluent management or containment is the sole goal of therapy�
Note: V.A.C. VeraFlo™ Therapy should not be used in the presence of
enteric fistula to prevent wound contamination.
Protect Periwound skin: Consider use of a skin preparation product to protect periwound
skin� Do not allow foam to overlap onto intact skin� Protect fragile/friable periwound skin with
additional V�A�C� Drape, skin protectant, hydrocolloid, or other transparent film� Multiple layers
®
of the V�A�C� Drape may decrease the moisture vapor transmission rate, which may increase the
®
risk of maceration� If any signs of irritation or sensitivity to the drape, foam, or tubing assembly
appear, discontinue use and consult a physician� To avoid trauma to the periwound skin, do not
pull or stretch the drape over the foam dressing during drape application� Extra caution should be
used for patients with neuropathic etiologies or circulatory compromise�
Therapy or V�A�C� VeraFlo™ Therapy to help minimize sensory
®
Therapy Clinical Guidelines for more detail� V�A�C�
®
9
therapy: Continuous V�A�C�
®
Therapy and V�A�C� VeraFlo™ Therapy
®
Therapy is not
®
®
Therapy and
®
®